Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus KEFLEX.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic